117 HR 7640 IH: To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”). U.S. House of Representatives 2022-05-03 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS2d SessionH. R. 7640IN THE HOUSE OF REPRESENTATIVESMay 3, 2022Mr. Bilirakis (for himself and Mr. Butterfield) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs).

1.

Reauthorization of grants and contracts for development of orphan drugs

Section 5(c) of the Orphan Drug Act (21 U.S.C. 360ee(c)) is amended by striking 2018 through 2022 and inserting 2023 through 2027.